Lilly told a federal appeals court its decision in the drug company's 340B contract pharmacy lawsuit "will have profound consequences for the integrity of the national healthcare system."
Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court
A federal district court’s ruling last October that federal law requires drug manufacturers to deliver 340B purchased drugs to contract pharmacies conflicts with two other courts’ conclusions, “upsets the delicate statutory balance Congress struck, and raises serious constitutional problems,” drug manufacturer Eli Lilly told a federal appeals court last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.